🎉 M&A multiples are live!
Check it out!

Lyell Immunopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Lyell Immunopharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Lyell Immunopharma Overview

About Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.


Founded

2018

HQ

United States of America
Employees

300

Website

lyell.com

Financials

LTM Revenue $43K

LTM EBITDA -$311M

EV

-$180M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Lyell Immunopharma Financials

Lyell Immunopharma has a last 12-month revenue of $43K and a last 12-month EBITDA of -$311M.

In the most recent fiscal year, Lyell Immunopharma achieved revenue of $0.1M and an EBITDA of -$201M.

Lyell Immunopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Lyell Immunopharma valuation multiples based on analyst estimates

Lyell Immunopharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.1M $0.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$227M -$201M XXX XXX XXX
EBITDA Margin -174429% -328923% XXX XXX XXX
Net Profit -$183M -$235M XXX XXX XXX
Net Margin -140860% -384643% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Lyell Immunopharma Stock Performance

As of April 15, 2025, Lyell Immunopharma's stock price is $0.

Lyell Immunopharma has current market cap of $131M, and EV of -$180M.

See Lyell Immunopharma trading valuation data

Lyell Immunopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$180M $131M XXX XXX XXX XXX $-1.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Lyell Immunopharma Valuation Multiples

As of April 15, 2025, Lyell Immunopharma has market cap of $131M and EV of -$180M.

Lyell Immunopharma's trades at -4149.4x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Lyell Immunopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Lyell Immunopharma and 10K+ public comps

Lyell Immunopharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$180M XXX XXX XXX
EV/Revenue -2955.7x XXX XXX XXX
EV/EBITDA 0.9x XXX XXX XXX
P/E -0.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Lyell Immunopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Lyell Immunopharma Valuation Multiples

Lyell Immunopharma's NTM/LTM revenue growth is -100%

Lyell Immunopharma's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $0.7M for the same period.

Over next 12 months, Lyell Immunopharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Lyell Immunopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Lyell Immunopharma and other 10K+ public comps

Lyell Immunopharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -53% XXX XXX XXX XXX
EBITDA Margin -328923% XXX XXX XXX XXX
EBITDA Growth -12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0K XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 85313% XXX XXX XXX XXX
R&D Expenses to Revenue 281316% XXX XXX XXX XXX
Opex to Revenue 361205% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Lyell Immunopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Lyell Immunopharma M&A and Investment Activity

Lyell Immunopharma acquired  XXX companies to date.

Last acquisition by Lyell Immunopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Lyell Immunopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Lyell Immunopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Lyell Immunopharma

When was Lyell Immunopharma founded? Lyell Immunopharma was founded in 2018.
Where is Lyell Immunopharma headquartered? Lyell Immunopharma is headquartered in United States of America.
How many employees does Lyell Immunopharma have? As of today, Lyell Immunopharma has 300 employees.
Who is the CEO of Lyell Immunopharma? Lyell Immunopharma's CEO is Dr. Lynn Seely,M.D..
Is Lyell Immunopharma publicy listed? Yes, Lyell Immunopharma is a public company listed on NAS.
What is the stock symbol of Lyell Immunopharma? Lyell Immunopharma trades under LYEL ticker.
When did Lyell Immunopharma go public? Lyell Immunopharma went public in 2021.
Who are competitors of Lyell Immunopharma? Similar companies to Lyell Immunopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Lyell Immunopharma? Lyell Immunopharma's current market cap is $131M
What is the current revenue of Lyell Immunopharma? Lyell Immunopharma's last 12-month revenue is $43K.
What is the current EBITDA of Lyell Immunopharma? Lyell Immunopharma's last 12-month EBITDA is -$311M.
What is the current EV/Revenue multiple of Lyell Immunopharma? Current revenue multiple of Lyell Immunopharma is -4149.4x.
What is the current EV/EBITDA multiple of Lyell Immunopharma? Current EBITDA multiple of Lyell Immunopharma is 0.6x.
What is the current revenue growth of Lyell Immunopharma? Lyell Immunopharma revenue growth between 2023 and 2024 was -53%.
Is Lyell Immunopharma profitable? Yes, Lyell Immunopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.